Glaukos Announces Participation in the William Blair 41st Annual Growth Stock Conference

Rhea-AI Summary

Glaukos Corporation (NYSE: GKOS), a leader in ophthalmic medical technology, will present at the William Blair 41st Annual Growth Stock Conference on June 2, 2021, at 4:40 p.m. CDT. The event will be available via live and archived webcast on their Investors website. Glaukos specializes in innovative therapies for glaucoma and corneal disorders, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) with devices like the iStent and its successors. The company's advancements aim to transform treatment paradigms in ophthalmology.

Positive

• Scheduled participation in a significant investment conference, enhancing visibility.
• Focus on innovative glaucoma treatments with a proven product track record.

Negative

• None.

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the William Blair 41^st Annual Growth Stock Conference on Wednesday, June 2, 2021, at 4:40 p.m. CDT.

A live and archived webcast for this event will be available in the Investors section of the Glaukos website at http://investors.glaukos.com.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent^®, its first MIGS device, in the United States in 2012, its next-generation iStent inject^® device in the United States in 2018 and most recently, its iStent inject W device in the United States in 2020. In corneal health, Glaukos’ proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210519005089/en/

FAQ

What is the date of Glaukos Corporation's presentation at the William Blair conference?

Glaukos Corporation is scheduled to present on June 2, 2021.

What time will Glaukos Corporation's presentation start at the William Blair conference?

The presentation will start at 4:40 p.m. CDT.

Where can I watch Glaukos Corporation's presentation?

The presentation will be available via live and archived webcast on the Investors section of the Glaukos website.

What areas does Glaukos Corporation focus on?

Glaukos focuses on novel therapies for glaucoma, corneal disorders, and retinal diseases.

What products has Glaukos Corporation developed?

Glaukos has developed the iStent and its successors, which are part of their Micro-Invasive Glaucoma Surgery platform.